nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Ifosfamide—germ cell cancer	0.0113	0.498	CbGbCtD
Rifaximin—CYP3A4—Vinblastine—germ cell cancer	0.00598	0.264	CbGbCtD
Rifaximin—CYP3A4—Etoposide—germ cell cancer	0.00539	0.238	CbGbCtD
Rifaximin—Angiopathy—Ifosfamide—germ cell cancer	0.00352	0.0036	CcSEcCtD
Rifaximin—Mediastinal disorder—Ifosfamide—germ cell cancer	0.0035	0.00358	CcSEcCtD
Rifaximin—Cough—Bleomycin—germ cell cancer	0.00345	0.00353	CcSEcCtD
Rifaximin—Pneumonia—Etoposide—germ cell cancer	0.00344	0.00352	CcSEcCtD
Rifaximin—Ill-defined disorder—Dactinomycin—germ cell cancer	0.00342	0.0035	CcSEcCtD
Rifaximin—Infestation NOS—Etoposide—germ cell cancer	0.00342	0.00349	CcSEcCtD
Rifaximin—Infestation—Etoposide—germ cell cancer	0.00342	0.00349	CcSEcCtD
Rifaximin—Anaemia—Dactinomycin—germ cell cancer	0.00341	0.00349	CcSEcCtD
Rifaximin—Mental disorder—Ifosfamide—germ cell cancer	0.0034	0.00348	CcSEcCtD
Rifaximin—Malnutrition—Ifosfamide—germ cell cancer	0.00338	0.00346	CcSEcCtD
Rifaximin—Chest pain—Bleomycin—germ cell cancer	0.00337	0.00344	CcSEcCtD
Rifaximin—Myalgia—Bleomycin—germ cell cancer	0.00337	0.00344	CcSEcCtD
Rifaximin—Discomfort—Bleomycin—germ cell cancer	0.00333	0.0034	CcSEcCtD
Rifaximin—Malaise—Dactinomycin—germ cell cancer	0.00333	0.0034	CcSEcCtD
Rifaximin—Decreased appetite—Vinblastine—germ cell cancer	0.00332	0.0034	CcSEcCtD
Rifaximin—Urine output increased—Methotrexate—germ cell cancer	0.00331	0.00338	CcSEcCtD
Rifaximin—Urinary tract disorder—Cisplatin—germ cell cancer	0.00331	0.00338	CcSEcCtD
Rifaximin—Urethral disorder—Cisplatin—germ cell cancer	0.00328	0.00336	CcSEcCtD
Rifaximin—Pain—Vinblastine—germ cell cancer	0.00327	0.00334	CcSEcCtD
Rifaximin—Constipation—Vinblastine—germ cell cancer	0.00327	0.00334	CcSEcCtD
Rifaximin—Confusional state—Bleomycin—germ cell cancer	0.00325	0.00333	CcSEcCtD
Rifaximin—Anaphylactic shock—Bleomycin—germ cell cancer	0.00323	0.0033	CcSEcCtD
Rifaximin—Infection—Bleomycin—germ cell cancer	0.00321	0.00328	CcSEcCtD
Rifaximin—Feeling abnormal—Vinblastine—germ cell cancer	0.00315	0.00322	CcSEcCtD
Rifaximin—Myalgia—Dactinomycin—germ cell cancer	0.00314	0.00321	CcSEcCtD
Rifaximin—Ill-defined disorder—Ifosfamide—germ cell cancer	0.00314	0.00321	CcSEcCtD
Rifaximin—Gastrointestinal pain—Vinblastine—germ cell cancer	0.00312	0.0032	CcSEcCtD
Rifaximin—Anaemia—Ifosfamide—germ cell cancer	0.00312	0.0032	CcSEcCtD
Rifaximin—Tinnitus—Cisplatin—germ cell cancer	0.00312	0.00319	CcSEcCtD
Rifaximin—Flushing—Cisplatin—germ cell cancer	0.00311	0.00318	CcSEcCtD
Rifaximin—Discomfort—Dactinomycin—germ cell cancer	0.0031	0.00317	CcSEcCtD
Rifaximin—Angioedema—Ifosfamide—germ cell cancer	0.00309	0.00316	CcSEcCtD
Rifaximin—Anorexia—Bleomycin—germ cell cancer	0.00308	0.00315	CcSEcCtD
Rifaximin—Hypoaesthesia—Etoposide—germ cell cancer	0.00305	0.00312	CcSEcCtD
Rifaximin—Malaise—Ifosfamide—germ cell cancer	0.00305	0.00312	CcSEcCtD
Rifaximin—Vertigo—Ifosfamide—germ cell cancer	0.00304	0.00311	CcSEcCtD
Rifaximin—Urinary tract disorder—Etoposide—germ cell cancer	0.00303	0.0031	CcSEcCtD
Rifaximin—Polyuria—Methotrexate—germ cell cancer	0.00302	0.00309	CcSEcCtD
Rifaximin—Abdominal pain—Vinblastine—germ cell cancer	0.00302	0.00309	CcSEcCtD
Rifaximin—Mediastinal disorder—Cisplatin—germ cell cancer	0.00302	0.00309	CcSEcCtD
Rifaximin—Hypotension—Bleomycin—germ cell cancer	0.00302	0.00309	CcSEcCtD
Rifaximin—Urethral disorder—Etoposide—germ cell cancer	0.00301	0.00308	CcSEcCtD
Rifaximin—Infection—Dactinomycin—germ cell cancer	0.00299	0.00306	CcSEcCtD
Rifaximin—Cough—Ifosfamide—germ cell cancer	0.00295	0.00302	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.00294	0.00301	CcSEcCtD
Rifaximin—Malnutrition—Cisplatin—germ cell cancer	0.00291	0.00298	CcSEcCtD
Rifaximin—Dyspnoea—Bleomycin—germ cell cancer	0.00288	0.00294	CcSEcCtD
Rifaximin—Chest pain—Ifosfamide—germ cell cancer	0.00288	0.00294	CcSEcCtD
Rifaximin—Arthralgia—Ifosfamide—germ cell cancer	0.00288	0.00294	CcSEcCtD
Rifaximin—Myalgia—Ifosfamide—germ cell cancer	0.00288	0.00294	CcSEcCtD
Rifaximin—Flatulence—Cisplatin—germ cell cancer	0.00287	0.00294	CcSEcCtD
Rifaximin—Anorexia—Dactinomycin—germ cell cancer	0.00287	0.00294	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	0.00286	0.00292	CcSEcCtD
Rifaximin—Flushing—Etoposide—germ cell cancer	0.00285	0.00291	CcSEcCtD
Rifaximin—Discomfort—Ifosfamide—germ cell cancer	0.00284	0.00291	CcSEcCtD
Rifaximin—Hypersensitivity—Vinblastine—germ cell cancer	0.00282	0.00288	CcSEcCtD
Rifaximin—Dermatitis exfoliative—Methotrexate—germ cell cancer	0.00281	0.00288	CcSEcCtD
Rifaximin—Decreased appetite—Bleomycin—germ cell cancer	0.00281	0.00287	CcSEcCtD
Rifaximin—Muscle spasms—Cisplatin—germ cell cancer	0.0028	0.00287	CcSEcCtD
Rifaximin—Angiopathy—Etoposide—germ cell cancer	0.00278	0.00285	CcSEcCtD
Rifaximin—Confusional state—Ifosfamide—germ cell cancer	0.00278	0.00285	CcSEcCtD
Rifaximin—Mediastinal disorder—Etoposide—germ cell cancer	0.00276	0.00283	CcSEcCtD
Rifaximin—Pain—Bleomycin—germ cell cancer	0.00276	0.00282	CcSEcCtD
Rifaximin—Anaphylactic shock—Ifosfamide—germ cell cancer	0.00276	0.00282	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.00274	0.00281	CcSEcCtD
Rifaximin—Asthenia—Vinblastine—germ cell cancer	0.00274	0.00281	CcSEcCtD
Rifaximin—Infection—Ifosfamide—germ cell cancer	0.00274	0.0028	CcSEcCtD
Rifaximin—Tremor—Cisplatin—germ cell cancer	0.00273	0.00279	CcSEcCtD
Rifaximin—Nervous system disorder—Ifosfamide—germ cell cancer	0.0027	0.00277	CcSEcCtD
Rifaximin—Ill-defined disorder—Cisplatin—germ cell cancer	0.0027	0.00277	CcSEcCtD
Rifaximin—Anaemia—Cisplatin—germ cell cancer	0.00269	0.00276	CcSEcCtD
Rifaximin—Skin disorder—Ifosfamide—germ cell cancer	0.00268	0.00274	CcSEcCtD
Rifaximin—Hyperhidrosis—Ifosfamide—germ cell cancer	0.00267	0.00273	CcSEcCtD
Rifaximin—Feeling abnormal—Bleomycin—germ cell cancer	0.00266	0.00272	CcSEcCtD
Rifaximin—Anorexia—Ifosfamide—germ cell cancer	0.00263	0.00269	CcSEcCtD
Rifaximin—Malaise—Cisplatin—germ cell cancer	0.00263	0.00269	CcSEcCtD
Rifaximin—Decreased appetite—Dactinomycin—germ cell cancer	0.00262	0.00268	CcSEcCtD
Rifaximin—Diarrhoea—Vinblastine—germ cell cancer	0.00261	0.00268	CcSEcCtD
Rifaximin—Fatigue—Dactinomycin—germ cell cancer	0.0026	0.00266	CcSEcCtD
Rifaximin—Back pain—Etoposide—germ cell cancer	0.00258	0.00264	CcSEcCtD
Rifaximin—Hypotension—Ifosfamide—germ cell cancer	0.00258	0.00264	CcSEcCtD
Rifaximin—Pain—Dactinomycin—germ cell cancer	0.00257	0.00263	CcSEcCtD
Rifaximin—Muscle spasms—Etoposide—germ cell cancer	0.00257	0.00263	CcSEcCtD
Rifaximin—Urticaria—Bleomycin—germ cell cancer	0.00256	0.00262	CcSEcCtD
Rifaximin—Body temperature increased—Bleomycin—germ cell cancer	0.00255	0.00261	CcSEcCtD
Rifaximin—Dizziness—Vinblastine—germ cell cancer	0.00253	0.00259	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.00251	0.00257	CcSEcCtD
Rifaximin—Myalgia—Cisplatin—germ cell cancer	0.00248	0.00254	CcSEcCtD
Rifaximin—Feeling abnormal—Dactinomycin—germ cell cancer	0.00248	0.00254	CcSEcCtD
Rifaximin—Ill-defined disorder—Etoposide—germ cell cancer	0.00248	0.00253	CcSEcCtD
Rifaximin—Anaemia—Etoposide—germ cell cancer	0.00247	0.00252	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	0.00246	0.00252	CcSEcCtD
Rifaximin—Gastrointestinal pain—Dactinomycin—germ cell cancer	0.00246	0.00252	CcSEcCtD
Rifaximin—Dyspnoea—Ifosfamide—germ cell cancer	0.00246	0.00252	CcSEcCtD
Rifaximin—Discomfort—Cisplatin—germ cell cancer	0.00245	0.00251	CcSEcCtD
Rifaximin—Vomiting—Vinblastine—germ cell cancer	0.00243	0.00249	CcSEcCtD
Rifaximin—Malaise—Etoposide—germ cell cancer	0.00241	0.00246	CcSEcCtD
Rifaximin—Vertigo—Etoposide—germ cell cancer	0.0024	0.00245	CcSEcCtD
Rifaximin—Decreased appetite—Ifosfamide—germ cell cancer	0.0024	0.00245	CcSEcCtD
Rifaximin—Headache—Vinblastine—germ cell cancer	0.00239	0.00245	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.00238	0.00244	CcSEcCtD
Rifaximin—Body temperature increased—Dactinomycin—germ cell cancer	0.00238	0.00243	CcSEcCtD
Rifaximin—Abdominal pain—Dactinomycin—germ cell cancer	0.00238	0.00243	CcSEcCtD
Rifaximin—Fatigue—Ifosfamide—germ cell cancer	0.00238	0.00243	CcSEcCtD
Rifaximin—Anaphylactic shock—Cisplatin—germ cell cancer	0.00238	0.00243	CcSEcCtD
Rifaximin—Hypersensitivity—Bleomycin—germ cell cancer	0.00238	0.00243	CcSEcCtD
Rifaximin—Infection—Cisplatin—germ cell cancer	0.00236	0.00242	CcSEcCtD
Rifaximin—Pain—Ifosfamide—germ cell cancer	0.00236	0.00241	CcSEcCtD
Rifaximin—Constipation—Ifosfamide—germ cell cancer	0.00236	0.00241	CcSEcCtD
Rifaximin—Loss of consciousness—Etoposide—germ cell cancer	0.00235	0.0024	CcSEcCtD
Rifaximin—Nervous system disorder—Cisplatin—germ cell cancer	0.00233	0.00239	CcSEcCtD
Rifaximin—Cough—Etoposide—germ cell cancer	0.00233	0.00238	CcSEcCtD
Rifaximin—Asthenia—Bleomycin—germ cell cancer	0.00232	0.00237	CcSEcCtD
Rifaximin—Skin disorder—Cisplatin—germ cell cancer	0.00231	0.00236	CcSEcCtD
Rifaximin—Hyperhidrosis—Cisplatin—germ cell cancer	0.0023	0.00235	CcSEcCtD
Rifaximin—Pruritus—Bleomycin—germ cell cancer	0.00228	0.00234	CcSEcCtD
Rifaximin—Feeling abnormal—Ifosfamide—germ cell cancer	0.00227	0.00233	CcSEcCtD
Rifaximin—Chest pain—Etoposide—germ cell cancer	0.00227	0.00233	CcSEcCtD
Rifaximin—Nausea—Vinblastine—germ cell cancer	0.00227	0.00232	CcSEcCtD
Rifaximin—Anorexia—Cisplatin—germ cell cancer	0.00227	0.00232	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	0.00226	0.00231	CcSEcCtD
Rifaximin—Gastrointestinal pain—Ifosfamide—germ cell cancer	0.00226	0.00231	CcSEcCtD
Rifaximin—Discomfort—Etoposide—germ cell cancer	0.00225	0.0023	CcSEcCtD
Rifaximin—Hypotension—Cisplatin—germ cell cancer	0.00222	0.00227	CcSEcCtD
Rifaximin—Hypersensitivity—Dactinomycin—germ cell cancer	0.00222	0.00227	CcSEcCtD
Rifaximin—Abdominal discomfort—Methotrexate—germ cell cancer	0.0022	0.00225	CcSEcCtD
Rifaximin—Confusional state—Etoposide—germ cell cancer	0.0022	0.00225	CcSEcCtD
Rifaximin—Urticaria—Ifosfamide—germ cell cancer	0.00219	0.00224	CcSEcCtD
Rifaximin—Abdominal pain—Ifosfamide—germ cell cancer	0.00218	0.00223	CcSEcCtD
Rifaximin—Body temperature increased—Ifosfamide—germ cell cancer	0.00218	0.00223	CcSEcCtD
Rifaximin—Anaphylactic shock—Etoposide—germ cell cancer	0.00218	0.00223	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.00217	0.00222	CcSEcCtD
Rifaximin—Infection—Etoposide—germ cell cancer	0.00216	0.00221	CcSEcCtD
Rifaximin—Asthenia—Dactinomycin—germ cell cancer	0.00216	0.00221	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—germ cell cancer	0.00215	0.0022	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—germ cell cancer	0.00215	0.0022	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—germ cell cancer	0.00213	0.00218	CcSEcCtD
Rifaximin—Dyspnoea—Cisplatin—germ cell cancer	0.00212	0.00217	CcSEcCtD
Rifaximin—Skin disorder—Etoposide—germ cell cancer	0.00212	0.00216	CcSEcCtD
Rifaximin—Hyperhidrosis—Etoposide—germ cell cancer	0.00211	0.00215	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—germ cell cancer	0.00209	0.00214	CcSEcCtD
Rifaximin—Anorexia—Etoposide—germ cell cancer	0.00208	0.00212	CcSEcCtD
Rifaximin—Decreased appetite—Cisplatin—germ cell cancer	0.00207	0.00211	CcSEcCtD
Rifaximin—Diarrhoea—Dactinomycin—germ cell cancer	0.00206	0.00211	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—germ cell cancer	0.00206	0.00211	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.00205	0.0021	CcSEcCtD
Rifaximin—Vomiting—Bleomycin—germ cell cancer	0.00205	0.0021	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—germ cell cancer	0.00205	0.00209	CcSEcCtD
Rifaximin—Infestation—Methotrexate—germ cell cancer	0.00205	0.00209	CcSEcCtD
Rifaximin—Depression—Methotrexate—germ cell cancer	0.00204	0.00209	CcSEcCtD
Rifaximin—Hypotension—Etoposide—germ cell cancer	0.00204	0.00208	CcSEcCtD
Rifaximin—Rash—Bleomycin—germ cell cancer	0.00203	0.00208	CcSEcCtD
Rifaximin—Pain—Cisplatin—germ cell cancer	0.00203	0.00208	CcSEcCtD
Rifaximin—Dermatitis—Bleomycin—germ cell cancer	0.00203	0.00208	CcSEcCtD
Rifaximin—Hypersensitivity—Ifosfamide—germ cell cancer	0.00203	0.00208	CcSEcCtD
Rifaximin—Asthenia—Ifosfamide—germ cell cancer	0.00198	0.00202	CcSEcCtD
Rifaximin—Feeling abnormal—Cisplatin—germ cell cancer	0.00196	0.002	CcSEcCtD
Rifaximin—Pruritus—Ifosfamide—germ cell cancer	0.00195	0.002	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—germ cell cancer	0.00195	0.002	CcSEcCtD
Rifaximin—Dyspnoea—Etoposide—germ cell cancer	0.00194	0.00199	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—germ cell cancer	0.00193	0.00197	CcSEcCtD
Rifaximin—Nausea—Bleomycin—germ cell cancer	0.00192	0.00196	CcSEcCtD
Rifaximin—Vomiting—Dactinomycin—germ cell cancer	0.00191	0.00196	CcSEcCtD
Rifaximin—Rash—Dactinomycin—germ cell cancer	0.0019	0.00194	CcSEcCtD
Rifaximin—Decreased appetite—Etoposide—germ cell cancer	0.00189	0.00194	CcSEcCtD
Rifaximin—Diarrhoea—Ifosfamide—germ cell cancer	0.00189	0.00193	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Etoposide—germ cell cancer	0.00188	0.00192	CcSEcCtD
Rifaximin—Body temperature increased—Cisplatin—germ cell cancer	0.00188	0.00192	CcSEcCtD
Rifaximin—Fatigue—Etoposide—germ cell cancer	0.00188	0.00192	CcSEcCtD
Rifaximin—Constipation—Etoposide—germ cell cancer	0.00186	0.00191	CcSEcCtD
Rifaximin—Pain—Etoposide—germ cell cancer	0.00186	0.00191	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—germ cell cancer	0.00185	0.00189	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—germ cell cancer	0.00184	0.00188	CcSEcCtD
Rifaximin—Dizziness—Ifosfamide—germ cell cancer	0.00182	0.00187	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—germ cell cancer	0.00182	0.00187	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—germ cell cancer	0.00181	0.00186	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—germ cell cancer	0.0018	0.00184	CcSEcCtD
Rifaximin—Feeling abnormal—Etoposide—germ cell cancer	0.0018	0.00184	CcSEcCtD
Rifaximin—Nausea—Dactinomycin—germ cell cancer	0.00179	0.00183	CcSEcCtD
Rifaximin—Gastrointestinal pain—Etoposide—germ cell cancer	0.00178	0.00182	CcSEcCtD
Rifaximin—Vomiting—Ifosfamide—germ cell cancer	0.00175	0.00179	CcSEcCtD
Rifaximin—Hypersensitivity—Cisplatin—germ cell cancer	0.00175	0.00179	CcSEcCtD
Rifaximin—Rash—Ifosfamide—germ cell cancer	0.00174	0.00178	CcSEcCtD
Rifaximin—Dermatitis—Ifosfamide—germ cell cancer	0.00174	0.00178	CcSEcCtD
Rifaximin—Urticaria—Etoposide—germ cell cancer	0.00173	0.00177	CcSEcCtD
Rifaximin—Body temperature increased—Etoposide—germ cell cancer	0.00172	0.00176	CcSEcCtD
Rifaximin—Abdominal pain—Etoposide—germ cell cancer	0.00172	0.00176	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—germ cell cancer	0.00171	0.00175	CcSEcCtD
Rifaximin—Asthenia—Cisplatin—germ cell cancer	0.00171	0.00175	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—germ cell cancer	0.00167	0.0017	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—germ cell cancer	0.00166	0.00169	CcSEcCtD
Rifaximin—Nausea—Ifosfamide—germ cell cancer	0.00164	0.00168	CcSEcCtD
Rifaximin—Diarrhoea—Cisplatin—germ cell cancer	0.00163	0.00166	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—germ cell cancer	0.00161	0.00165	CcSEcCtD
Rifaximin—Hypersensitivity—Etoposide—germ cell cancer	0.0016	0.00164	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—germ cell cancer	0.0016	0.00164	CcSEcCtD
Rifaximin—Asthenia—Etoposide—germ cell cancer	0.00156	0.0016	CcSEcCtD
Rifaximin—Back pain—Methotrexate—germ cell cancer	0.00155	0.00158	CcSEcCtD
Rifaximin—Pruritus—Etoposide—germ cell cancer	0.00154	0.00158	CcSEcCtD
Rifaximin—Vomiting—Cisplatin—germ cell cancer	0.00151	0.00155	CcSEcCtD
Rifaximin—Rash—Cisplatin—germ cell cancer	0.0015	0.00153	CcSEcCtD
Rifaximin—Dermatitis—Cisplatin—germ cell cancer	0.0015	0.00153	CcSEcCtD
Rifaximin—Diarrhoea—Etoposide—germ cell cancer	0.00149	0.00153	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—germ cell cancer	0.00148	0.00152	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—germ cell cancer	0.00148	0.00151	CcSEcCtD
Rifaximin—Malaise—Methotrexate—germ cell cancer	0.00144	0.00148	CcSEcCtD
Rifaximin—Dizziness—Etoposide—germ cell cancer	0.00144	0.00147	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—germ cell cancer	0.00144	0.00147	CcSEcCtD
Rifaximin—Nausea—Cisplatin—germ cell cancer	0.00141	0.00145	CcSEcCtD
Rifaximin—Cough—Methotrexate—germ cell cancer	0.0014	0.00143	CcSEcCtD
Rifaximin—Vomiting—Etoposide—germ cell cancer	0.00139	0.00142	CcSEcCtD
Rifaximin—Rash—Etoposide—germ cell cancer	0.00137	0.00141	CcSEcCtD
Rifaximin—Dermatitis—Etoposide—germ cell cancer	0.00137	0.0014	CcSEcCtD
Rifaximin—Headache—Etoposide—germ cell cancer	0.00136	0.0014	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—germ cell cancer	0.00136	0.00139	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—germ cell cancer	0.00136	0.00139	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—germ cell cancer	0.00136	0.00139	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	0.00135	0.00138	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—germ cell cancer	0.00134	0.00138	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—germ cell cancer	0.00132	0.00135	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—germ cell cancer	0.0013	0.00134	CcSEcCtD
Rifaximin—Infection—Methotrexate—germ cell cancer	0.0013	0.00133	CcSEcCtD
Rifaximin—Nausea—Etoposide—germ cell cancer	0.00129	0.00132	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—germ cell cancer	0.00128	0.00131	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—germ cell cancer	0.00127	0.0013	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—germ cell cancer	0.00126	0.00129	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—germ cell cancer	0.00124	0.00127	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—germ cell cancer	0.00122	0.00125	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.00119	0.00122	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—germ cell cancer	0.00118	0.00121	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—germ cell cancer	0.00116	0.00119	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—germ cell cancer	0.00113	0.00116	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.00113	0.00115	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—germ cell cancer	0.00112	0.00115	CcSEcCtD
Rifaximin—Pain—Methotrexate—germ cell cancer	0.00112	0.00114	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—germ cell cancer	0.00108	0.0011	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—germ cell cancer	0.00107	0.00109	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—germ cell cancer	0.00104	0.00106	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—germ cell cancer	0.00103	0.00106	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—germ cell cancer	0.00103	0.00106	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—germ cell cancer	0.000961	0.000984	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—germ cell cancer	0.000936	0.000958	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—germ cell cancer	0.000923	0.000945	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—germ cell cancer	0.000893	0.000913	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—germ cell cancer	0.000863	0.000883	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—germ cell cancer	0.00083	0.000849	CcSEcCtD
Rifaximin—Rash—Methotrexate—germ cell cancer	0.000823	0.000842	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—germ cell cancer	0.000822	0.000841	CcSEcCtD
Rifaximin—Headache—Methotrexate—germ cell cancer	0.000817	0.000836	CcSEcCtD
Rifaximin—Nausea—Methotrexate—germ cell cancer	0.000775	0.000793	CcSEcCtD
